Financial Performance - The company's operating revenue for Q1 2023 was ¥129,643,591.18, representing a 57.17% increase compared to ¥82,485,669.07 in the same period last year[4] - The net loss attributable to shareholders was ¥707,071.25, a 97.21% improvement from a net loss of ¥25,339,030.73 in the previous year[4] - The net cash flow from operating activities was ¥3,397,477.87, a significant turnaround from a negative cash flow of ¥32,253,006.95 in the same period last year, marking a 110.53% increase[4] - The company reported a net loss of CNY 228,901,186.14 for Q1 2023, compared to a loss of CNY 228,194,114.89 in the previous year[13] - The net profit for Q1 2023 was a loss of CNY 3,150,084.93, an improvement from a loss of CNY 36,395,477.46 in the same period last year[16] - The operating profit for Q1 2023 was a loss of CNY 3,105,393.10, significantly better than the loss of CNY 36,949,175.55 in Q1 2022[16] - The total comprehensive income for Q1 2023 was a loss of CNY 3,182,717.04, compared to a loss of CNY 36,704,772.00 in Q1 2022[16] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,672,547,396.21, reflecting a 1.21% increase from ¥1,652,618,278.43 at the end of the previous year[4] - Cash and cash equivalents at the end of Q1 2023 were CNY 151,850,814.49, an increase from CNY 120,113,833.90 at the beginning of the year[11] - Total assets as of March 31, 2023, were CNY 1,672,547,396.21, compared to CNY 1,635,408,931.74 at the beginning of the year[13] - Total liabilities increased to CNY 1,106,976,510.32 from CNY 1,066,655,328.80 at the start of the year[13] - The company's equity attributable to shareholders was CNY 571,761,045.51, a slight decrease from CNY 572,500,748.87 at the beginning of the year[13] Cash Flow and Management - The cash received from sales of goods and services increased by 52.5%, totaling an increase of ¥46,340,000 compared to the previous year[6] - The company received tax refunds amounting to CNY 1,355,460.09 in Q1 2023, compared to CNY 807,080.32 in Q1 2022, indicating better cash flow management[19] - The company incurred financial expenses of CNY 8,273,195.31 in Q1 2023, down from CNY 11,223,616.88 in Q1 2022, reflecting improved cost management[16] Research and Development - The company reported a decrease in research and development expenses by 51.77%, amounting to a reduction of ¥720,000 compared to the previous year[6] - Research and development expenses decreased to CNY 669,850.77 in Q1 2023 from CNY 1,388,879.00 in Q1 2022, indicating a reduction in R&D investment[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 51,221, with no preferred shareholders[8] - The company's basic earnings per share improved by 97.35%, reaching -¥0.0008 compared to -¥0.0302 in the same period last year[4] - The basic and diluted earnings per share for Q1 2023 were both -0.0008, an improvement from -0.0302 in Q1 2022[16] Future Plans - The company plans to focus on expanding its market presence and developing new technologies in the upcoming quarters[12]

证券代码：002622 证券简称：永大集团 吉林永大集团股份有限公司 投资者关系活动记录表 编号：001 | --- | --- | --- | |-----------------------------|-----------------------------------|------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | □ 其他 | | 参与单位名称及 | | 国泰君安：孔祥、张为、张天阳、周津宇、李树林 | | 人员姓名 | 东北证券：张经纬 兴业证券：段涛涛 | | | | | | | 时间 | 2016 年 02 月 | 29 日 | | 地点 | 吉林永大集团股份有限公司 | | | 上市公司接待人 | | 副总经理、董事会秘书 黄佳慧 | | 员姓名 | 证券事务代表 郑颖 | | | 投资者关系活动 主要内容介绍 | 一、 | 公司目前总体经营管理 ...

融钰集团股份有限公司 2022 年第三季度报告 2022 年 10 月 证券代码：002622 证券简称：融钰集团 公告编号：2022-062 □是 否 2 融钰集团股份有限公司 融钰集团股份有限公司 2022 年第三季度报告 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 融钰集团股份有限公司 2022 年第三季度报告 公司是否需追溯调整或重述以前年度会计数据 一、主要财务数据 适用 □不适用 （一） 主要会计数据和财务指标 单位：元 | 项目 | 本报告期金额 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | --- | | 非流动资产处置损益（包括 已计提资产减值准备的冲销 | -25,101.8 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥211,861,084.40, representing a 331.50% increase compared to ¥49,098,637.57 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was -¥30,559,032.20, a decrease of 429.97% from ¥9,261,137.11 in the previous year[19]. - The net cash flow from operating activities was -¥36,173,487.44, down 762.30% from ¥5,461,770.60 in the same period last year[19]. - The total assets at the end of the reporting period were ¥1,707,270,734.76, a decrease of 4.74% from ¥1,792,171,860.35 at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company were ¥828,063,896.24, down 3.61% from ¥859,104,421.04 at the end of the previous year[19]. - The basic earnings per share were -¥0.0364, a decline of 430.91% compared to ¥0.0110 in the same period last year[19]. - The diluted earnings per share were also -¥0.0364, reflecting the same percentage decline as basic earnings per share[19]. - The weighted average return on net assets was -3.62%, a decrease of 4.64% from 1.02% in the previous year[19]. - The company reported a significant increase in revenue, reaching ¥211,861,084.40, a 331.50% increase compared to ¥49,098,637.57 in the previous year, primarily due to the acquisition of Delun Medical[40]. - Operating costs rose to ¥131,603,797.34, reflecting a 427.79% increase from ¥24,935,067.59, driven by the expanded revenue scale following the acquisition[40]. - Sales expenses surged to ¥49,886,520.74, marking a 1,966.26% increase from ¥2,414,335.47, also attributed to the acquisition of Delun Medical[40]. - The company reported a net profit loss of CNY 44,311,085.97 for the first half of 2022, compared to a net profit of CNY 9,261,137.11 in the same period of 2021[134]. - The total profit loss amounted to CNY 46,471,448.90, a stark contrast to the profit of CNY 9,650,546.99 reported in the first half of 2021[134]. Business Operations - The company has established a dual business operation model focusing on "oral medical services + industrial manufacturing" after transferring 100% equity of its subsidiary, Zhiyong Technology, to Jiangxi Yuru Data Technology Development Co., Ltd., retaining 45% equity[27]. - The dental service segment has expanded its operations to cover Guangzhou and Foshan, with a strong regional brand influence, and aims to enhance its market penetration through the opening of new clinics[28][32]. - The company has invested in children's dental specialty clinics in Yuexiu and Panyu districts, which are expected to become new growth points for performance, with one recognized as a "Guangzhou Children's Oral Health Science Base"[33]. - The digitalization of dental services has been a key focus, with over 90% usage rate of digital guides in dental implant procedures, positioning the company as a leader in the industry[30]. - The company operates 1 dental hospital and 24 direct chain clinics, covering over 24,000 square meters and equipped with more than 350 dental chairs, making it one of the largest dental service providers in South China[30]. - The company has completed the opening of four new dental clinics during the reporting period, with plans for further expansion in the Guangzhou and Foshan areas[32]. - The electrical business segment, through its subsidiary Jilin Yongda Electric Switch Co., Ltd., has developed a comprehensive marketing network across more than 20 provinces, providing integrated pre-sale, in-sale, and after-sale services[33]. - The company is committed to the digital transformation of the manufacturing sector, aligning with national strategies to enhance the competitiveness and quality of the manufacturing industry[27]. - The dental service industry is expected to grow significantly due to increasing public awareness of oral health and rising disposable income, supported by national health policies[29]. - The company has established a "1+N" business model for dental services, integrating flagship and community clinics to enhance service delivery and patient experience[31]. Financial Position - Cash and cash equivalents at the end of the reporting period were ¥153,440,265.83, down from ¥192,343,847.31 at the end of the previous year[49]. - Long-term equity investments increased by 2.22% to ¥574,535,179.04, representing 33.65% of total assets[49]. - Short-term borrowings decreased to ¥120,348,333.00, a reduction of 0.28% from the previous year[49]. - The total restricted assets amount to ¥804,929,053.64, including cash deposits of ¥1,800,049.79, receivables of ¥22,700,000.00, and long-term equity investments of ¥574,282,349.21 due to litigation freezes and pledges[52]. - The company has no significant equity or non-equity investments during the reporting period[53]. - The company reported no derivative investments during the reporting period[55]. - The company has not undergone any bankruptcy restructuring or significant contract issues during the reporting period[85][97]. - The total liabilities decreased to CNY 873,275,405.30 from CNY 913,383,952.32, marking a reduction of about 4.4%[127]. - The total equity attributable to shareholders decreased to CNY 828,063,896.24 from CNY 859,104,421.04, a decline of approximately 3.6%[127]. Risk Management - The report highlights potential risks and uncertainties that may affect future performance, urging investors to be cautious[4]. - The company faces regulatory risks related to the dental implant market, with potential impacts from centralized procurement policies[62]. - The company is committed to enhancing its operational management and internal controls to address challenges from business expansion in the dental medical service sector[63]. - The company aims to improve talent retention strategies to mitigate risks associated with the loss of specialized medical personnel[64]. - The company expects that the ongoing impact of the COVID-19 pandemic will continue to affect its operating performance in the future[66]. - The company has established a referral mechanism to mitigate the impact of pandemic-related service interruptions, leveraging its multiple clinic locations[66]. - The company plans to maintain strict risk control and scientific investment decision-making processes to ensure long-term development[68]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 51,795[111]. - Guangzhou Huiyin Rife Investment Partnership holds 23.81% of shares, totaling 200,000,000 shares[111]. - Shaanxi International Trust Company holds 3.84% of shares, totaling 32,263,200 shares[111]. - The total number of limited sale condition shares is 24,750, accounting for 0.00% of the total[109]. - The total number of unrestricted sale condition shares is 839,975,250, accounting for 100.00% of the total[109]. - There were no changes in the number of shares held by major shareholders during the reporting period[111]. - The company did not implement any share buyback or reduction during the reporting period[110]. - There were no new share issuances or transfers reported[110]. - The company has not disclosed any impacts on financial metrics due to share changes[110]. Corporate Governance - The company disclosed the resignation of the vice chairman and general manager, along with the election of a new chairman and appointment of a new general manager[104]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period[82]. - There were no significant lawsuits or arbitration matters reported during the period, with a total of 4,634.88 thousand yuan involved in minor cases[87]. - The company has not engaged in any major related party transactions during the reporting period[89]. - The company has not experienced any violations regarding external guarantees during the reporting period[83]. - The company maintains a good integrity status for both itself and its major shareholders during the reporting period[88]. Social Responsibility - The company actively engages in social responsibility, focusing on product safety, environmental protection, and energy conservation, leading to improved product quality and enhanced industry competitiveness[78]. - Since the outbreak of the pandemic, the company has organized 72 batches of over 430 medical personnel to support large-scale nucleic acid testing and vaccination efforts in Guangzhou and Foshan, contributing to public health[79]. - The company emphasizes energy conservation by introducing advanced technologies and gradually phasing out high-energy-consuming equipment[78]. - The company has established a comprehensive oral healthcare service system under its subsidiary, aiming to meet the needs of dental patients and support the "Healthy China" initiative[78]. Future Outlook - The company plans to focus on market expansion and new product development in the upcoming quarters[146]. - The management provided a revenue guidance for the second half of 2022, expecting a growth of 5% to 10% compared to the first half of the year[147]. - Future performance guidance remains optimistic, with expectations of revenue growth driven by new technologies and market strategies[146].

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a year-over-year growth of 20%[165]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year 2021, representing a year-over-year growth of 15%[161]. - The company achieved a total revenue of ¥168,106,984.77 in 2021, representing a 47.02% increase compared to ¥114,345,046.98 in 2020[51]. - The company's operating revenue for 2021 was ¥168,106,984.77, representing a 47.02% increase compared to ¥114,345,046.98 in 2020[21]. - The electrical switch industry contributed ¥95,402,981.23, accounting for 56.75% of total revenue, with a year-on-year growth of 28.38%[51]. - The newly acquired dental medical service sector generated ¥49,181,650.06, making up 29.26% of total revenue, marking its first contribution since the acquisition[51]. - The software development sector saw a decline in revenue to ¥21,445,305.76, down 43.19% from the previous year[52]. - The company reported a net profit margin of 12% for 2021, an increase from 10% in the previous year, indicating improved profitability[161]. - The company reported a net profit attributable to shareholders was -¥75,981,538.91, an improvement of 74.43% from -¥297,124,345.16 in the previous year[21]. Acquisitions and Business Expansion - The company completed the acquisition of controlling interest in Delun Medical on November 18, 2021, making it a subsidiary[18]. - The company completed the acquisition of Guangzhou Delun Medical Group in November 2021, contributing ¥49,180,000 to the fourth quarter's revenue[25]. - The company completed the acquisition of 51% of Delun Medical in November 2021, marking its entry into the dental medical service industry[46]. - The company acquired 51% of Guangdong Delun Medical Group for a total of 245 million CNY, enhancing its presence in the dental medical service industry[92]. - The company plans to optimize the profitability and sustainable development of Delun Medical under its strategic management[93]. - The company aims to actively pursue mergers and acquisitions in the dental medical field to enhance its service capabilities and achieve synergistic effects[95]. Operational Efficiency and Cost Management - The company is focusing on enhancing its internal control and governance to improve operational efficiency and profitability[48]. - The company has implemented strict cost management measures to optimize its operational efficiency and control expenses[48]. - The company aims to reduce operational costs by 10% in 2022 through efficiency improvements and process optimization[157]. - The management team emphasized a commitment to improving operational efficiency, targeting a 5% reduction in costs over the next year[123]. - The company aims to reduce operational costs by 15% through efficiency improvements and process optimization in the upcoming year[165]. Market Trends and Industry Insights - The oral health industry is experiencing rapid growth, supported by national health policies aimed at improving public oral health awareness and services[34]. - The dental medical service industry is experiencing rapid growth, supported by favorable policies and increasing demand for oral health services[48]. - The oral health service market in China reached a scale of 103 billion yuan in 2019, with a year-on-year growth of 7.29%, and is expected to reach 124 billion yuan by 2021[37]. - The oral health awareness among the Chinese population has improved, with over 84% of citizens holding a positive attitude towards oral health[36]. Governance and Compliance - The company has established a transparent information disclosure system to enhance communication with investors[103]. - The company has not engaged in any investor communication activities during the reporting period[100]. - The company has held 4 shareholder meetings and 8 board meetings, ensuring compliance with governance regulations[102]. - The company maintains independence from its controlling shareholders in business, personnel, assets, and financial aspects[105]. - The company has committed to strict compliance with laws and regulations, ensuring no major breaches of trust or legal issues[164]. Research and Development - Research and development expenses increased by 30%, totaling 150 million RMB, to support new technology initiatives[121]. - The company has implemented a performance management system to link employee compensation with company performance[138]. - The number of R&D personnel decreased by 9.09% from 77 in 2020 to 70 in 2021, with the proportion of R&D personnel dropping from 19.00% to 5.00%[68]. - R&D investment increased by 23.20% from ¥7,996,687.44 in 2020 to ¥9,851,754.19 in 2021, while the proportion of R&D investment to operating revenue decreased from 6.99% to 5.86%[68]. Financial Position and Assets - The company’s total assets and liabilities as of December 31, 2021, were reported, reflecting its financial position[18]. - The total assets at the end of 2021 were ¥1,792,171,860.35, a 33.69% increase from ¥1,340,539,193.47 at the end of 2020[21]. - Cash and cash equivalents decreased to ¥192,343,847.31, accounting for 10.73% of total assets, down from 14.50%[76]. - The company reported an asset impairment provision of ¥16,630,900 and a credit impairment loss of ¥619,200 during the reporting period[72]. Employee and Management Structure - The total number of employees at the end of the reporting period was 1,365, with 1,344 from major subsidiaries[136]. - The company has 46 employees with a master's degree or above, and 1,062 with a college degree or below[137]. - The company has a diverse board with members holding various professional backgrounds, including finance, law, and healthcare[113][114][115][116]. - The company has maintained a stable management team with no significant turnover in key positions since 2020[110]. Social Responsibility and Sustainability - The company actively engages in social responsibility initiatives, including energy conservation, environmental protection, and employee rights protection[152]. - The company has committed to sustainability initiatives, aiming for a 50% reduction in carbon emissions by 2025[168]. - The company has implemented measures to improve product quality and safety, as well as to enhance production safety and reduce energy consumption[152]. Risks and Challenges - The company’s future operational plans and targets are subject to market conditions and uncertainties, highlighting investment risks[4]. - The company acknowledges potential policy risks related to dental implant procurement policies that may impact service prices and market demand[97]. - The company is focused on enhancing operational management and internal controls to address challenges arising from business expansion in the dental medical sector[98].

Financial Performance - The company's revenue for Q1 2022 was ¥82,485,669.07, representing a 395.85% increase compared to ¥16,635,191.36 in the same period last year[3] - The net profit attributable to shareholders was -¥25,339,030.73, a decrease of 693.98% from -¥3,191,400.03 year-on-year[3] - The total operating revenue for the first quarter of 2022 was ¥82,485,669.07, a significant increase from ¥16,635,191.36 in the same period last year, representing a growth of 394.4%[18] - The net loss for the first quarter was ¥36,395,477.46, compared to a net loss of ¥3,191,400.03 in the previous year, reflecting a deterioration in performance[20] - The total comprehensive loss for the first quarter was ¥36,704,772.00, compared to a loss of ¥7,329,294.08 in the previous year[21] - Basic and diluted earnings per share were both reported at -¥0.0302, a decline from -¥0.0038 in the same quarter last year[21] Cash Flow - The net cash flow from operating activities was -¥32,253,006.95, a decline of 892.49% compared to ¥4,069,851.03 in the previous year[3] - The cash flow from operating activities showed a net outflow of ¥32,253,006.95, contrasting with a net inflow of ¥4,069,851.03 in the same quarter last year[22] - The company reported a net cash inflow from investing activities of ¥54,470,751.65, primarily from the recovery of investments totaling ¥55,000,000.00[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,719,382,737.43, down 4.06% from ¥1,792,171,860.35 at the end of the previous year[3] - Total current assets decreased from 418,800,603.81 to 357,708,188.53, a decline of approximately 14.6%[16] - Cash and cash equivalents decreased from 192,343,847.31 to 186,794,081.84, a decrease of about 2.9%[15] - Accounts receivable decreased from 47,221,817.21 to 42,991,129.08, a decline of approximately 9.4%[16] - The company's total liabilities decreased by ¥23,000,000, reflecting a reduction in debt obligations during the reporting period[9] - Total liabilities decreased from 913,383,952.32 to 877,299,601.40, a reduction of about 4.0%[17] - The company's equity attributable to shareholders decreased from 859,104,421.04 to 833,456,095.77, a decrease of about 3.0%[17] - The company’s total liabilities and equity decreased from ¥1,792,171,860.35 to ¥1,719,382,737.43, indicating a reduction in financial leverage[18] Expenses - The company reported an increase in sales expenses by ¥19,830,000, primarily due to the acquisition of 51% of Delun Medical and the expansion into the dental medical sector[7] - The company’s management expenses increased by ¥27,770,000, also attributed to the acquisition and related business expansion[7] - The total operating costs for the first quarter were ¥124,438,676.52, up from ¥30,562,144.94, indicating an increase of 307.5%[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 57,916[12] - The largest shareholder, Guangzhou Huiyin Rifen Investment Partnership, holds 23.81% of shares, totaling 200,000,000 shares[12] - The number of shares held by the top ten unrestricted shareholders totals 200,000,000 and 32,263,200 shares respectively[12] Other Financial Information - The company received government subsidies amounting to ¥113,105.57, contributing to its financial performance[5] - The company reported a significant reduction in other receivables from 95,402,811.61 to 41,848,819.04, a decline of approximately 56.1%[16] - The company has not undergone an audit for the first quarter report[24]

Financial Performance - The company's operating revenue for Q3 2021 was ¥27,295,409.54, a decrease of 4.51% compared to the same period last year, while year-to-date revenue increased by 31.22% to ¥76,394,047.11[6] - The net profit attributable to shareholders for Q3 2021 was a loss of ¥8,070,454.04, representing a decline of 271.41% year-on-year, while year-to-date net profit increased by 104.30% to ¥1,190,683.07[6] - Basic and diluted earnings per share for Q3 2021 were both -¥0.0096, a decrease of 271.41% compared to the same period last year, while year-to-date earnings per share increased by 104.24% to ¥0.0014[6] - Total operating revenue for Q3 2021 was CNY 76,394,047.11, an increase of 31.1% compared to CNY 58,217,553.26 in the same period last year[29] - Net profit for Q3 2021 was CNY 1,190,683.07, a significant recovery from a net loss of CNY 27,711,292.48 in Q3 2020[30] - Basic and diluted earnings per share for the quarter were both ¥0.0014, a recovery from a loss of ¥0.0330 per share in the previous year[31] - The total comprehensive income attributable to the parent company was -¥20,094,935.58, compared to -¥18,765,711.38 in the same period last year, reflecting a decline of about 7.1%[31] Assets and Liabilities - Total assets at the end of Q3 2021 were ¥1,375,052,149.42, an increase of 2.57% from the end of the previous year[7] - The company's equity attributable to shareholders decreased by 2.31% to ¥850,968,343.79 compared to the end of the previous year[7] - The company's total assets reached CNY 1,375,052,149.42, compared to CNY 1,340,539,193.47 at the end of the previous quarter[27] - Current liabilities increased to CNY 434,561,291.61 from CNY 379,614,972.28 in the previous quarter[26] - The total equity attributable to shareholders was CNY 850,968,343.79, down from CNY 871,063,279.37 in the previous quarter[27] - The total liabilities stood at approximately ¥469.48 million, indicating a debt-to-equity ratio of about 54%[39] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥9,907,822.34, a decrease of 69.14% compared to the previous year[6] - The net cash flow from operating activities was ¥9,907,822.34, down from ¥32,107,785.48 in the previous year, indicating a decline of about 69.1%[34] - The cash inflow from operating activities totaled ¥81,268,842.35, down from ¥107,364,752.48 in the previous year, a decrease of approximately 24.3%[34] - The cash outflow from operating activities was ¥71,361,020.01, slightly lower than ¥75,256,967.00 in the previous year, indicating a decrease of about 5.3%[34] - The total cash and cash equivalents at the end of the period increased to ¥223,411,061.97, compared to ¥101,130,216.04 at the end of the previous year, representing a growth of approximately 120.5%[35] - The net cash flow from investment activities was ¥75,000,000.00, significantly higher than ¥30,055,072.05 in the previous year, marking an increase of about 149.2%[34] - The net cash flow from financing activities was -¥52,958,214.08, worsening from -¥32,365,343.73 in the same period last year, indicating a decline of approximately 63.8%[34] Shareholder Information - The total number of common shareholders at the end of the reporting period is 61,273[17] - The largest shareholder, Guangzhou Huiyin Rifeng Investment Partnership, holds 23.81% of shares, totaling 200,000,000 shares[17] Strategic Initiatives - The company plans to acquire 51% of Guangzhou Delun Medical Investment Co., Ltd. for a total cash consideration of 246 million RMB, with 141 million RMB for 30% from one party and 105 million RMB for 21% from another[19] - The assessed value of Delun Medical's total equity as of May 31, 2021, is approximately 569.62 million RMB[20] - The company aims to enhance its profitability by integrating high-quality assets, particularly through the acquisition of Delun Medical, which focuses on oral healthcare services[21] - The company is actively expanding into the oral healthcare service industry, which has significant market potential[21] - The upcoming shareholder meeting on November 11, 2021, will review the related matters of the asset acquisition[22] - The company has identified the need to improve its core business profitability to support sustainable development[21] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[30] Research and Development - Research and development expenses for Q3 2021 were CNY 6,098,463.04, compared to CNY 5,597,304.27 in Q3 2020, indicating a focus on innovation[30] Other Financial Metrics - Investment income decreased by ¥19,601,300, or 45.13%, due to reduced net profit from the company's associate, Fushun Bank[12] - The company experienced a 97.76% decrease in credit impairment losses compared to the same period last year, reflecting a reduction in provisions made in the previous year[13] - The company reported an investment income of CNY 23,828,877.58, a decrease from CNY 43,430,179.18 in the same period last year[30] - The company has not undergone an audit for the third quarter report, which may affect the reliability of the financial data presented[41]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥49,098,637.57, representing a 65.69% increase compared to ¥29,632,396.01 in the same period last year[19]. - The net profit attributable to shareholders was ¥9,261,137.11, a significant turnaround from a loss of ¥32,419,460.31 in the previous year, marking a 128.57% improvement[19]. - The net profit after deducting non-recurring gains and losses was ¥8,346,837.84, compared to a loss of ¥33,835,256.29 in the same period last year, reflecting a 124.67% increase[19]. - The basic earnings per share increased to ¥0.0110 from a loss of ¥0.0386, showing a 128.50% improvement[19]. - The total operating revenue for the first half of 2021 reached ¥49,098,637.57, a significant increase of 65.6% compared to ¥29,632,396.01 in the same period of 2020[136]. - The company reported a net profit of ¥9,261,137.11 for the first half of 2021, a turnaround from a net loss of ¥32,419,460.31 in the first half of 2020[138]. - The total comprehensive income for the first half of 2021 was ¥20,166,731.97, a significant recovery from a loss of ¥28,851,587.81 in the previous year[139]. - The company reported a net loss of approximately RMB 8.21 million for the first half of 2021, indicating a significant decline in profitability[163]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,401,582,549.01, up 4.55% from ¥1,340,539,193.47 at the end of the previous year[19]. - The total liabilities increased to CNY 510,007,955.13 from CNY 469,476,440.14, reflecting a rise of about 8.6%[130]. - The company's total equity at the end of the reporting period was 1,246,920.90 yuan, down from 1,284,000.00 yuan at the beginning of the period, indicating a reduction of approximately 2.9%[156]. - The total liabilities at the end of the current period were not specified, indicating a need for further financial clarity[160]. Cash Flow - The net cash flow from operating activities was ¥5,461,770.60, a decrease of 53.63% compared to ¥11,779,170.25 in the same period last year[19]. - The cash flow from operating activities was ¥46,512,302.47, compared to ¥54,557,946.14 in the first half of 2020, indicating a decrease in cash inflow from operations[145]. - The total cash inflow from investment activities was ¥45,000,000.00, compared to ¥64,048,993.15 in the previous year, reflecting a decline of 29.8%[147]. - The cash outflow for debt repayment was ¥7,000,000.00, a decrease from ¥80,586,946.35 in the previous year, indicating a reduction in debt servicing[147]. Investments and Acquisitions - The company plans to acquire control of Guangzhou Delun Medical Investment Co., Ltd. through a cash payment, as approved in the board meetings held on May 27, 2021[5]. - The company holds a 7.39% stake in Fushun Bank, valued at 607,698,687.78 RMB, with a market value of 22,700,000 shares[52]. - The total profit from investment activities was ¥24,843,081.04, accounting for 257.43% of total profit, indicating a strong performance from the investment in Fushun Bank[43]. Operational Highlights - The company primarily engages in the research, production, and sales of permanent magnet switches and high/low voltage switchgear, along with software development and leasing of office space[27]. - The subsidiary Jilin Yongda Electric has established a marketing network covering over 20 provinces, providing comprehensive services including pre-sale, in-sale, and after-sale support[27]. - Yongda Electric has upgraded its products to meet the requirements of the national smart grid, enhancing features such as fault judgment, recording, and network interaction[27]. - The company has made breakthroughs in the electric furnace and chemical industries, focusing on project stability and success rates to drive overall performance growth[28]. Research and Development - Research and development expenses increased to ¥4,061,809.26, up from ¥3,825,219.23, indicating a focus on innovation[136]. - The company emphasizes a customer and market-driven approach in its R&D innovation system, ensuring continuous technological progress[33]. - The company has accumulated nearly 100 proprietary software products and has received multiple provincial and municipal technology advancement awards[33]. Corporate Governance and Compliance - The company has no significant environmental violations and complies with environmental protection regulations, with no penalties reported during the period[70]. - The integrity status of the company and its major shareholders is reported to be good during the reporting period[82]. - There were no related party transactions in daily operations during the reporting period[83]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 71,259[113]. - Guangzhou Huiyin Rifen Investment Partnership holds 23.81% of the shares, totaling 200,000,000 common shares[114]. - The second largest shareholder, Shaanxi International Trust Co., Ltd., holds 3.84% with 32,263,200 common shares[115]. Financial Reporting and Standards - The semi-annual financial report has not been audited[126]. - The financial statements are prepared in RMB[127]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring accurate financial reporting[174].

2021 年第一季度报告全文 2021-018 融钰集团股份有限公司 2021 年第一季度报告全文 融钰集团股份有限公司 2 融钰集团股份有限公司 2021 年第一季度报告全文 2021 年 4 月 第二节 公司基本情况 一、主要会计数据和财务指标 1 融钰集团股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陆璐、主管会计工作负责人邓强及会计机构负责人(会计主管人 员)杨恩龙声明：保证季度报告中财务报表的真实、准确、完整。 | 项目 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益（包括已计提资产减值准备的冲销部分） | 107,052.48 | | | 计入当期损益的政府补助（与企业业务密切相关，按照国家统 一标准定额或定量享受的政府补助除外） | 185,447.19 | | | 除上述各项之外的其他营业外收入和支出 | 177,4 ...

Financial Performance - The company reported a net loss attributable to shareholders of CNY 297,124,345.16 for the year[43]. - The company's operating revenue for 2020 was ¥114,345,046.98, a decrease of 26.38% compared to ¥155,321,874.62 in 2019[18]. - The net profit attributable to shareholders was -¥297,124,345.16, representing a decline of 4,093.11% from ¥7,440,930.97 in the previous year[18]. - The company reported a basic earnings per share of -¥0.3537, down from ¥0.0089 in 2019, marking a decline of 4,074.16%[18]. - The company reported a net profit after deducting non-recurring gains and losses of -¥328,122,627.47, compared to ¥3,235,682.04 in 2019, a decrease of 10,240.76%[18]. - The company reported a net profit decrease of 27.62% year-on-year, with a net profit margin of -0.88% for the year 2020[93]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2020, representing a year-over-year increase of 15%[195]. Shareholder Structure - The company’s major shareholder, Guangzhou Huiyin, holds 23.81% of the total shares, making it the largest shareholder[16]. - The largest shareholder, Guangzhou Huiyin Rifen Investment Partnership (Limited Partnership), holds 23.81% of the shares, totaling 200,000,000 shares[170]. - The second largest shareholder, Shaanxi International Trust Co., Ltd., holds 32,263,200 shares, representing a significant stake in the company[170]. - The company has a strategic relationship with its top shareholders, indicating potential alignment in future business strategies[170]. - The company has no controlling shareholder, and the actual controller is Jie Zhikuan, who has over 19 years of experience in the financial sector[175]. Business Operations - The company has not made any changes to its main business operations since its listing, continuing to focus on its core products[16]. - The company has undergone a change in actual control, with Beijing Shoutuo Ronghui becoming the actual controller after a partnership agreement with Guangzhou Huiyin[16]. - The company has maintained its existing business without launching new ventures during the reporting period, focusing on the leasing of various equipment and trade financing services[32]. - The company has established a strong customer base in traditional industries such as steel, chemicals, and coal, enhancing its market position[37]. - The company has transitioned its sales management model from a regional to an industry-based approach, focusing on clean energy and enhancing project stability through regular follow-ups[30]. Research and Development - The company is committed to continuous innovation in its traditional business of permanent magnet switches and software development, with a focus on expanding product categories and improving performance[43]. - The company has developed nearly 100 proprietary software products and has undertaken several major national and provincial scientific research projects[43]. - The company’s R&D investment in 2020 amounted to ¥7,996,687.44, a decrease of 13.52% compared to ¥9,247,013.41 in 2019[70]. - The company completed several R&D projects in 2020, including the development of the YDMC-100 permanent magnet circuit breaker and the ZN85 permanent magnet vacuum circuit breaker[64]. - The company aims to enhance its R&D capabilities and service capacity while expanding into new technologies, products, and markets[100]. Financial Management - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[5]. - The company has focused on cost management, improving internal controls, and optimizing asset structure to enhance operational efficiency[44]. - The company will strengthen its internal control system and risk management to adapt to the expanding market scale and business scope[104]. - The company has initiated the liquidation of underperforming subsidiaries to optimize its asset structure and reduce management costs[44]. - The company is committed to maintaining a strong leadership team to navigate market challenges and capitalize on new opportunities[190]. Market Strategy - The company plans to focus on the traditional permanent magnet switch industry while exploring collaborations with influential enterprises in target fields[101]. - The company aims to enhance product competitiveness and reduce production costs through the completion of R&D projects, thereby driving core competitiveness and business development[65]. - The company is expanding its market presence, targeting new regions with a planned investment of $50 million in marketing and infrastructure[156]. - The company plans to continue its focus on financial management and operational excellence to enhance shareholder value[188]. - The company aims to improve operational efficiency by implementing new management strategies, projected to reduce costs by 5%[195]. Corporate Governance - The company has appointed Zhonghua Certified Public Accountants as its auditor, with an audit fee of RMB 650,000 and a continuous service period of 15 years[124]. - The company has committed to reducing and regulating related party transactions to protect the interests of shareholders[113]. - The company will ensure that the interests of the listed company are not harmed by adhering to strict disclosure obligations regarding related party transactions[115]. - The company has a diverse board with members holding qualifications in law, finance, and management, which strengthens its governance structure[190]. - The company has seen a significant turnover in its board members, indicating a potential shift in strategic direction and governance[187]. Social Responsibility - The company actively participates in social responsibility initiatives, including environmental protection and employee rights[148]. - The company has implemented energy-saving measures and improved equipment to reduce energy consumption[148]. - The company contributed to pandemic relief efforts by donating during the COVID-19 outbreak[148]. - The company is committed to environmental sustainability, implementing new practices that reduce waste by 25%[161]. Regulatory Compliance - The company has faced regulatory scrutiny, resulting in a public reprimand from the Shenzhen Stock Exchange, but no financial penalties were imposed[196]. - There were no significant lawsuits or arbitration matters affecting the company during the reporting period, with total amounts involved in minor cases not reaching the disclosure threshold[125]. - The company did not experience any penalties or rectification issues during the reporting period[128].